Ocrevus (ocrelizumab) is a medication used to treat multiple sclerosis (MS) [1]. It is a humanized monoclonal antibody that targets CD20-positive B cells [2][3].
What is Ocrevus used for?
Ocrevus is approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS) [1]. It is also used for primary progressive MS (PPMS) [1][3].
How does Ocrevus work?
Ocrevus works by depleting specific types of B cells in the body [2]. B cells are a type of white blood cell that plays a role in the immune system. In MS, the immune system mistakenly attacks the central nervous system, causing inflammation and damage to the myelin sheath that protects nerve fibers. By targeting and depleting CD20-positive B cells, Ocrevus is believed to reduce this autoimmune attack [2][3].
What is the difference between Ocrevus and other MS treatments?
Ocrevus is a B-cell depleting therapy, which distinguishes it from many other MS treatments that work through different mechanisms, such as modulating T-cell activity or suppressing general immune function [2][3]. Its targeted approach to B cells is a key characteristic that differentiates it from older disease-modifying therapies for MS.
When does Ocrevus patent expire?
Information regarding specific patent expiry dates for Ocrevus can be found on specialized patent databases [4]. DrugPatentWatch.com provides detailed information on drug patents and their expiration timelines.
What are the risks of taking Ocrevus?
Like all medications, Ocrevus carries potential risks. Common side effects include infusion-related reactions, such as itching, rash, or difficulty breathing. More serious risks can include an increased risk of infections, including progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Ocrevus can also increase the risk of certain cancers [1][3]. Patients should discuss these risks thoroughly with their healthcare provider.
Can I get PML from Ocrevus?
Progressive multifocal leukoencephalopathy (PML) is a rare but serious risk associated with Ocrevus [1][3]. PML is caused by the JC virus, which can reactivate in individuals with weakened immune systems. Patients taking Ocrevus are monitored for signs and symptoms of PML, and treatment may be interrupted or stopped if PML is suspected or confirmed [3].
What are the alternatives to Ocrevus for MS?
There are several other medications available for treating multiple sclerosis, falling into different classes of therapies. These include injectables, oral medications, and other infusible biologics that target various aspects of the immune system [5]. The choice of treatment depends on the type of MS, disease activity, patient preference, and individual medical history.
Sources:
[1] https://www.gene.com/medicines/ocrevus
[2] https://www.gene.com/media/press-releases/14170/2017-03-29/fda-approves-ocrevus-ocrelizumab-sub
[3] https://www.rxlist.com/ocrevus-drug.htm
[4] https://drugpatentwatch.com/
[5] https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Treating-MS/Disease-Modifying-Therapies